share_log

Alliance Global Partners Maintains Buy on XORTX Therapeutics, Raises Price Target to $14

Benzinga ·  Jan 4 09:09

Alliance Global Partners analyst James Molloy maintains XORTX Therapeutics (NASDAQ:XRTX) with a Buy and raises the price target from $9 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment